Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Videos|November 9, 2015
Reasoning Behind Beers Criteria Updates
Todd Semla, MS, PharmD, BCPS, AGSF, of the Department of Veterans Affairs discusses the reasons for the recent changes made to the American Geriatrics Society Beers Criteria.
Advertisement
Todd Semla, MS, PharmD, BCPS, AGSF, of the Department of Veterans Affairs discusses the reasons for the recent changes made to the American Geriatrics Society Beers Criteria.
This video was recorded at ASCP's Annual Meeting and Exhibition in Las Vegas, Nevada in October 2015.
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Advertisement
Advertisement
Trending on Pharmacy Times
1
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
2
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
5